Wuhan Hvsen Biotechnology Co Ltd (300871) — Cash Flow Quality Index
Wuhan Hvsen Biotechnology Co Ltd (300871) has a Cash Flow Quality Index of 0.84x as of September 2025. Operating cash flow of CN¥59.06 Million is below net income of CN¥70.72 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash efficiency ratio of Wuhan Hvsen Biotechnology Co Ltd to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Wuhan Hvsen Biotechnology Co Ltd Cash Flow Quality Index (2016–2025)
Historical Cash Flow Quality Index for Wuhan Hvsen Biotechnology Co Ltd across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 300871 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)
Year-by-year earnings quality comparison for Wuhan Hvsen Biotechnology Co Ltd. For live market cap and the full company financial profile, see Wuhan Hvsen Biotechnology Co Ltd market cap and net worth.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.94x | CN¥238.45 Million | CN¥253.16 Million | ▼ -83.0% |
| 2023 | 5.54x | CN¥92.92 Million | CN¥16.78 Million | ▲ +201.9% |
| 2022 | 1.83x | CN¥96.68 Million | CN¥52.71 Million | ▲ +56.5% |
| 2021 | 1.17x | CN¥155.72 Million | CN¥132.87 Million | ▲ +264.0% |
| 2020 | 0.32x | CN¥48.35 Million | CN¥150.16 Million | ▼ -79.0% |
| 2019 | 1.53x | CN¥105.24 Million | CN¥68.77 Million | ▲ +418.0% |
| 2018 | 0.30x | CN¥21.10 Million | CN¥71.40 Million | ▼ -67.6% |
| 2017 | 0.91x | CN¥80.56 Million | CN¥88.41 Million | ▼ -25.0% |
| 2016 | 1.21x | CN¥60.00 Million | CN¥49.40 Million | — |